Okrido (Prednisolone Sodium Phosphate)

Prednisolone Sodium Phosphate is a systemic glucocorticoid used to manage inflammatory and immune‑mediated disorders.

• Severe allergic reactions: rapidly diminishes swelling, itching and airway obstruction.
• Asthma exacerbations: decreases airway inflammation and improves breathing.
• Rheumatoid arthritis: reduces joint pain, swelling and structural damage.
• Inflammatory bowel disease (e.g., ulcerative colitis): controls mucosal inflammation and induces remission.

• Prednisolone Sodium Phosphate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and regulates gene transcription. This action up‑regulates anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines, adhesion molecules, and enzymes, leading to reduced leukocyte migration, vascular permeability, and immune activation.

Prednisolone Sodium Phosphate may cause a range of adverse reactions, varying by dose and duration.

Common Side Effects

• Increased appetite and weight gain
• Insomnia or mood swings
• Elevated blood glucose levels
• Gastrointestinal discomfort or ulceration
• Fluid retention and mild hypertension

Serious or Rare Side Effects

• Adrenal insufficiency on abrupt discontinuation
• Severe infections due to immunosuppression
• Osteoporosis with long‑term use
• Cataracts or glaucoma
• Psychosis or severe mood disorders
• Thromboembolic events

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications.

• Assess infection risk: avoid use in uncontrolled systemic infections.
• Monitor blood glucose: adjust antidiabetic therapy as needed.
• Evaluate bone health: consider calcium/vitamin D supplementation for long‑term treatment.
• Review psychiatric history: watch for mood changes or psychosis.
• Check ocular health: periodic eye examinations are advised.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Prednisolone Sodium Phosphate can alter the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase glucocorticoid exposure.
• Live vaccines: risk of disseminated infection.
• NSAIDs: heightened risk of gastrointestinal bleeding.
• Anticoagulants (e.g., warfarin): enhanced anticoagulant effect.
• Diuretics: increased potassium loss.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: possible hyperglycemia, require dose adjustment.
• Antihypertensives: potential reduction in blood pressure control.
• Non‑live vaccines: may diminish immune response.
• Antifungals (moderate CYP3A4 inhibitors): monitor for increased steroid effects.